 | • レポートコード：D0GIR-02177 • 出版社/出版日：GlobalInfoResearch / 2020年9月23日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール • 産業分類：医療、製薬、バイオ |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、アンジオテンシン変換酵素阻害薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。アンジオテンシン変換酵素阻害薬の種類別市場規模（ベナゼプリル（ロテンシン）、カプトプリル、エナラプリル（バソテック）、フォシノプリル、リシノプリル（プリニルビル、ゼストリル）、モエキシプリル、ペリンドプリル、キナプリル（アクプリル）、ラミプリル（アルタース）、トランドラプリル）、用途別市場規模（冠動脈疾患、心不全、糖尿病、慢性腎臓病、心臓発作、強皮症、片頭痛、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Pfizer、Daiichi Sankyo, Inc、AstraZeneca、Abbott、Novartis AG、Merck、Sanofi ・地域別グローバル市場分析 2015年-2020年 ・アンジオテンシン変換酵素阻害薬の北米市場（アメリカ、カナダ、メキシコ） ・アンジオテンシン変換酵素阻害薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・アンジオテンシン変換酵素阻害薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・アンジオテンシン変換酵素阻害薬の南米市場（ブラジル、アルゼンチン） ・アンジオテンシン変換酵素阻害薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：ベナゼプリル（ロテンシン）、カプトプリル、エナラプリル（バソテック）、フォシノプリル、リシノプリル（プリニルビル、ゼストリル）、モエキシプリル、ペリンドプリル、キナプリル（アクプリル）、ラミプリル（アルタース）、トランドラプリル ・用途別分析：冠動脈疾患、心不全、糖尿病、慢性腎臓病、心臓発作、強皮症、片頭痛、その他 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The Angiotensin Converting Enzyme Inhibitors market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The most likely (base case) scenario is that the global Angiotensin Converting Enzyme Inhibitors sales will be xx in 2020 from Angiotensin Converting Enzyme Inhibitors million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Angiotensin Converting Enzyme Inhibitors market size is expected to grow at xx% or more annually for the next five years.
This report also researches and evaluates the impact of Covid-19 outbreak on the Angiotensin Converting Enzyme Inhibitors industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Angiotensin Converting Enzyme Inhibitors and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).
Market segmentation
Angiotensin Converting Enzyme Inhibitors market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Angiotensin Converting Enzyme Inhibitors market has been segmented into:
Benazepril (Lotensin)
Captopril
Enalapril (Vasotec)
Fosinopril
Lisinopril (Prinivil, Zestril)
Moexipril
Perindopril
Quinapril (Accupril)
Ramipril (Altace)
Trandolapril
By Application, Angiotensin Converting Enzyme Inhibitors has been segmented into:
Coronary Artery Disease
Heart Failure
Diabetes
Chronic Kidney Diseases
Heart Attacks
Scleroderma
Migraines
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Angiotensin Converting Enzyme Inhibitors market presented in the report. This section sheds light on the sales growth of different regional and country-level Angiotensin Converting Enzyme Inhibitors markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Angiotensin Converting Enzyme Inhibitors market.
The report offers in-depth assessment of the growth and other aspects of the Angiotensin Converting Enzyme Inhibitors market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Angiotensin Converting Enzyme Inhibitors Market Share Analysis
Angiotensin Converting Enzyme Inhibitors competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Angiotensin Converting Enzyme Inhibitors sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Angiotensin Converting Enzyme Inhibitors sales, revenue and market share for each player covered in this report.
The major players covered in Angiotensin Converting Enzyme Inhibitors are:
Pfizer
Daiichi Sankyo, Inc
AstraZeneca
Abbott
Novartis AG
Merck
Sanofi
Among other players domestic and global, Angiotensin Converting Enzyme Inhibitors market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
1 Angiotensin Converting Enzyme Inhibitors Market Overview
1.1 Product Overview and Scope of Angiotensin Converting Enzyme Inhibitors
1.2 Classification of Angiotensin Converting Enzyme Inhibitors by Type
1.2.1 Global Angiotensin Converting Enzyme Inhibitors Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Angiotensin Converting Enzyme Inhibitors Revenue Market Share by Type in 2019
1.2.3 Benazepril (Lotensin)
1.2.4 Captopril
1.2.5 Enalapril (Vasotec)
1.2.6 Fosinopril
1.2.7 Lisinopril (Prinivil, Zestril)
1.2.8 Moexipril
1.2.9 Perindopril
1.2.10 Quinapril (Accupril)
1.2.11 Ramipril (Altace)
1.2.12 Trandolapril
1.3 Global Angiotensin Converting Enzyme Inhibitors Market by Application
1.3.1 Overview: Global Angiotensin Converting Enzyme Inhibitors Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Coronary Artery Disease
1.3.3 Heart Failure
1.3.4 Diabetes
1.3.5 Chronic Kidney Diseases
1.3.6 Heart Attacks
1.3.7 Scleroderma
1.3.8 Migraines
1.3.9 Others
1.4 Global Angiotensin Converting Enzyme Inhibitors Market by Regions
1.4.1 Global Angiotensin Converting Enzyme Inhibitors Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Angiotensin Converting Enzyme Inhibitors (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Angiotensin Converting Enzyme Inhibitors Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Angiotensin Converting Enzyme Inhibitors Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Angiotensin Converting Enzyme Inhibitors Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Angiotensin Converting Enzyme Inhibitors Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Angiotensin Converting Enzyme Inhibitors Status and Prospect (2015-2025)
1.5 COVID-19 Outbreak: Angiotensin Converting Enzyme Inhibitors Industry Impact
1.5.1 COVID-19 Potential Implications for the Angiotensin Converting Enzyme Inhibitors
1.5.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Angiotensin Converting Enzyme Inhibitors
1.5.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.5.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.5.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.5.2 Opportunity Analysis in Covid-19 Crisis
1.5.3 Market Risk and Restraints
1.5.4 Market Driving Force
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Pfizer SWOT Analysis
2.1.4 Pfizer Product and Services
2.1.5 Pfizer Angiotensin Converting Enzyme Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.2 Daiichi Sankyo, Inc
2.2.1 Daiichi Sankyo, Inc Details
2.2.2 Daiichi Sankyo, Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Daiichi Sankyo, Inc SWOT Analysis
2.2.4 Daiichi Sankyo, Inc Product and Services
2.2.5 Daiichi Sankyo, Inc Angiotensin Converting Enzyme Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.3 AstraZeneca
2.3.1 AstraZeneca Details
2.3.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 AstraZeneca SWOT Analysis
2.3.4 AstraZeneca Product and Services
2.3.5 AstraZeneca Angiotensin Converting Enzyme Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.4 Abbott
2.4.1 Abbott Details
2.4.2 Abbott Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Abbott SWOT Analysis
2.4.4 Abbott Product and Services
2.4.5 Abbott Angiotensin Converting Enzyme Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.5 Novartis AG
2.5.1 Novartis AG Details
2.5.2 Novartis AG Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Novartis AG SWOT Analysis
2.5.4 Novartis AG Product and Services
2.5.5 Novartis AG Angiotensin Converting Enzyme Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.6 Merck
2.6.1 Merck Details
2.6.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Merck SWOT Analysis
2.6.4 Merck Product and Services
2.6.5 Merck Angiotensin Converting Enzyme Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.7 Sanofi
2.7.1 Sanofi Details
2.7.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Sanofi SWOT Analysis
2.7.4 Sanofi Product and Services
2.7.5 Sanofi Angiotensin Converting Enzyme Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Angiotensin Converting Enzyme Inhibitors Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Angiotensin Converting Enzyme Inhibitors Players Market Share
3.2.2 Top 10 Angiotensin Converting Enzyme Inhibitors Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Angiotensin Converting Enzyme Inhibitors Revenue and Market Share by Regions
4.2 North America Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
4.3 Europe Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
4.5 South America Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
5 North America Angiotensin Converting Enzyme Inhibitors Revenue by Countries
5.1 North America Angiotensin Converting Enzyme Inhibitors Revenue by Countries (2015-2020)
5.2 USA Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
5.3 Canada Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
5.4 Mexico Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
6 Europe Angiotensin Converting Enzyme Inhibitors Revenue by Countries
6.1 Europe Angiotensin Converting Enzyme Inhibitors Revenue by Countries (2015-2020)
6.2 Germany Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
6.3 UK Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
6.4 France Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
6.5 Russia Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
6.6 Italy Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Angiotensin Converting Enzyme Inhibitors Revenue by Countries
7.1 Asia-Pacific Angiotensin Converting Enzyme Inhibitors Revenue by Countries (2015-2020)
7.2 China Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
7.3 Japan Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
7.4 Korea Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
7.5 India Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
8 South America Angiotensin Converting Enzyme Inhibitors Revenue by Countries
8.1 South America Angiotensin Converting Enzyme Inhibitors Revenue by Countries (2015-2020)
8.2 Brazil Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
8.3 Argentina Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Angiotensin Converting Enzyme Inhibitors by Countries
9.1 Middle East & Africa Angiotensin Converting Enzyme Inhibitors Revenue by Countries (2015-2020)
9.2 Saudi Arabia Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
9.3 UAE Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
9.4 Egypt Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
9.5 South Africa Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Angiotensin Converting Enzyme Inhibitors Revenue and Market Share by Type (2015-2020)
10.2 Global Angiotensin Converting Enzyme Inhibitors Market Forecast by Type (2019-2024)
10.3 Benazepril (Lotensin) Revenue Growth Rate (2015-2025)
10.4 Captopril Revenue Growth Rate (2015-2025)
10.5 Enalapril (Vasotec) Revenue Growth Rate (2015-2025)
10.6 Fosinopril Revenue Growth Rate (2015-2025)
10.7 Lisinopril (Prinivil, Zestril) Revenue Growth Rate (2015-2025)
10.8 Moexipril Revenue Growth Rate (2015-2025)
10.9 Perindopril Revenue Growth Rate (2015-2025)
10.10 Quinapril (Accupril) Revenue Growth Rate (2015-2025)
10.11 Ramipril (Altace) Revenue Growth Rate (2015-2025)
10.12 Trandolapril Revenue Growth Rate (2015-2025)
11 Global Angiotensin Converting Enzyme Inhibitors Market Segment by Application
11.1 Global Angiotensin Converting Enzyme Inhibitors Revenue Market Share by Application (2015-2020)
11.2 Angiotensin Converting Enzyme Inhibitors Market Forecast by Application (2019-2024)
11.3 Coronary Artery Disease Revenue Growth (2015-2020)
11.4 Heart Failure Revenue Growth (2015-2020)
11.5 Diabetes Revenue Growth (2015-2020)
11.6 Chronic Kidney Diseases Revenue Growth (2015-2020)
11.7 Heart Attacks Revenue Growth (2015-2020)
11.8 Scleroderma Revenue Growth (2015-2020)
11.9 Migraines Revenue Growth (2015-2020)
11.10 Others Revenue Growth (2015-2020)
12 Global Angiotensin Converting Enzyme Inhibitors Market Size Forecast (2021-2025)
12.1 Global Angiotensin Converting Enzyme Inhibitors Market Size Forecast (2021-2025)
12.2 Global Angiotensin Converting Enzyme Inhibitors Market Forecast by Regions (2021-2025)
12.3 North America Angiotensin Converting Enzyme Inhibitors Revenue Market Forecast (2021-2025)
12.4 Europe Angiotensin Converting Enzyme Inhibitors Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Angiotensin Converting Enzyme Inhibitors Revenue Market Forecast (2021-2025)
12.6 South America Angiotensin Converting Enzyme Inhibitors Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Angiotensin Converting Enzyme Inhibitors Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Angiotensin Converting Enzyme Inhibitors Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Angiotensin Converting Enzyme Inhibitors by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Angiotensin Converting Enzyme Inhibitors Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Angiotensin Converting Enzyme Inhibitors Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global Angiotensin Converting Enzyme Inhibitors Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. Pfizer Corporate Information, Location and Competitors
Table 7. Pfizer Angiotensin Converting Enzyme Inhibitors Major Business
Table 8. Pfizer Angiotensin Converting Enzyme Inhibitors Total Revenue (USD Million) (2017-2018)
Table 9. Pfizer SWOT Analysis
Table 10. Pfizer Angiotensin Converting Enzyme Inhibitors Product and Solutions
Table 11. Pfizer Angiotensin Converting Enzyme Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. Daiichi Sankyo, Inc Corporate Information, Location and Competitors
Table 13. Daiichi Sankyo, Inc Angiotensin Converting Enzyme Inhibitors Major Business
Table 14. Daiichi Sankyo, Inc Angiotensin Converting Enzyme Inhibitors Total Revenue (USD Million) (2018-2019)
Table 15. Daiichi Sankyo, Inc SWOT Analysis
Table 16. Daiichi Sankyo, Inc Angiotensin Converting Enzyme Inhibitors Product and Solutions
Table 17. Daiichi Sankyo, Inc Angiotensin Converting Enzyme Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. AstraZeneca Corporate Information, Location and Competitors
Table 19. AstraZeneca Angiotensin Converting Enzyme Inhibitors Major Business
Table 20. AstraZeneca Angiotensin Converting Enzyme Inhibitors Total Revenue (USD Million) (2017-2018)
Table 21. AstraZeneca SWOT Analysis
Table 22. AstraZeneca Angiotensin Converting Enzyme Inhibitors Product and Solutions
Table 23. AstraZeneca Angiotensin Converting Enzyme Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. Abbott Corporate Information, Location and Competitors
Table 25. Abbott Angiotensin Converting Enzyme Inhibitors Major Business
Table 26. Abbott Angiotensin Converting Enzyme Inhibitors Total Revenue (USD Million) (2017-2018)
Table 27. Abbott SWOT Analysis
Table 28. Abbott Angiotensin Converting Enzyme Inhibitors Product and Solutions
Table 29. Abbott Angiotensin Converting Enzyme Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. Novartis AG Corporate Information, Location and Competitors
Table 31. Novartis AG Angiotensin Converting Enzyme Inhibitors Major Business
Table 32. Novartis AG Angiotensin Converting Enzyme Inhibitors Total Revenue (USD Million) (2017-2018)
Table 33. Novartis AG SWOT Analysis
Table 34. Novartis AG Angiotensin Converting Enzyme Inhibitors Product and Solutions
Table 35. Novartis AG Angiotensin Converting Enzyme Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. Merck Corporate Information, Location and Competitors
Table 37. Merck Angiotensin Converting Enzyme Inhibitors Major Business
Table 38. Merck Angiotensin Converting Enzyme Inhibitors Total Revenue (USD Million) (2017-2018)
Table 39. Merck SWOT Analysis
Table 40. Merck Angiotensin Converting Enzyme Inhibitors Product and Solutions
Table 41. Merck Angiotensin Converting Enzyme Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 42. Sanofi Corporate Information, Location and Competitors
Table 43. Sanofi Angiotensin Converting Enzyme Inhibitors Major Business
Table 44. Sanofi Angiotensin Converting Enzyme Inhibitors Total Revenue (USD Million) (2017-2018)
Table 45. Sanofi SWOT Analysis
Table 46. Sanofi Angiotensin Converting Enzyme Inhibitors Product and Solutions
Table 47. Sanofi Angiotensin Converting Enzyme Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 48. Global Angiotensin Converting Enzyme Inhibitors Revenue (Million USD) by Players (2015-2020)
Table 49. Global Angiotensin Converting Enzyme Inhibitors Revenue Share by Players (2015-2020)
Table 50. Global Angiotensin Converting Enzyme Inhibitors Revenue (Million USD) by Regions (2015-2020)
Table 51. Global Angiotensin Converting Enzyme Inhibitors Revenue Market Share by Regions (2015-2020)
Table 52. North America Angiotensin Converting Enzyme Inhibitors Revenue by Countries (2015-2020)
Table 53. North America Angiotensin Converting Enzyme Inhibitors Revenue Market Share by Countries (2015-2020)
Table 54. Europe Angiotensin Converting Enzyme Inhibitors Revenue (Million USD) by Countries (2015-2020)
Table 55. Asia-Pacific Angiotensin Converting Enzyme Inhibitors Revenue (Million USD) by Countries (2015-2020)
Table 56. South America Angiotensin Converting Enzyme Inhibitors Revenue by Countries (2015-2020)
Table 57. South America Angiotensin Converting Enzyme Inhibitors Revenue Market Share by Countries (2015-2020)
Table 58. Middle East and Africa Angiotensin Converting Enzyme Inhibitors Revenue (Million USD) by Countries (2015-2020)
Table 59. Middle East and Africa Angiotensin Converting Enzyme Inhibitors Revenue Market Share by Countries (2015-2020)
Table 60. Global Angiotensin Converting Enzyme Inhibitors Revenue (Million USD) by Type (2015-2020)
Table 61. Global Angiotensin Converting Enzyme Inhibitors Revenue Share by Type (2015-2020)
Table 62. Global Angiotensin Converting Enzyme Inhibitors Revenue Forecast by Type (2021-2025)
Table 63. Global Angiotensin Converting Enzyme Inhibitors Revenue by Application (2015-2020)
Table 64. Global Angiotensin Converting Enzyme Inhibitors Revenue Share by Application (2015-2020)
Table 65. Global Angiotensin Converting Enzyme Inhibitors Revenue Forecast by Application (2021-2025)
Table 66. Global Angiotensin Converting Enzyme Inhibitors Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Angiotensin Converting Enzyme Inhibitors Picture
Figure 2. Global Angiotensin Converting Enzyme Inhibitors Revenue Market Share by Type in 2019
Figure 3. Benazepril (Lotensin) Picture
Figure 4. Captopril Picture
Figure 5. Enalapril (Vasotec) Picture
Figure 6. Fosinopril Picture
Figure 7. Lisinopril (Prinivil, Zestril) Picture
Figure 8. Moexipril Picture
Figure 9. Perindopril Picture
Figure 10. Quinapril (Accupril) Picture
Figure 11. Ramipril (Altace) Picture
Figure 12. Trandolapril Picture
Figure 13. Angiotensin Converting Enzyme Inhibitors Revenue Market Share by Application in 2019
Figure 14. Coronary Artery Disease Picture
Figure 15. Heart Failure Picture
Figure 16. Diabetes Picture
Figure 17. Chronic Kidney Diseases Picture
Figure 18. Heart Attacks Picture
Figure 19. Scleroderma Picture
Figure 20. Migraines Picture
Figure 21. Others Picture
Figure 22. Global Angiotensin Converting Enzyme Inhibitors Revenue (USD Million) and Growth Rate (2015-2025)
Figure 23. North America Angiotensin Converting Enzyme Inhibitors Revenue (Million USD) and Growth Rate (2015-2025)
Figure 24. Europe Angiotensin Converting Enzyme Inhibitors Revenue (Million USD) and Growth Rate (2015-2025)
Figure 25. Asia-Pacific Angiotensin Converting Enzyme Inhibitors Revenue (Million USD) and Growth Rate (2015-2025)
Figure 26. South America Angiotensin Converting Enzyme Inhibitors Revenue (Million USD) and Growth Rate (2015-2025)
Figure 27. Middle East and Africa Angiotensin Converting Enzyme Inhibitors Revenue (Million USD) and Growth Rate (2015-2025)
Figure 28. Global Angiotensin Converting Enzyme Inhibitors Revenue (Million USD) and Growth Rate (2015-2025)
Figure 29. Global Angiotensin Converting Enzyme Inhibitors Revenue Share by Players in 2019
Figure 30. Global Top 5 Players Angiotensin Converting Enzyme Inhibitors Revenue Market Share in 2019
Figure 31. Global Top 10 Players Angiotensin Converting Enzyme Inhibitors Revenue Market Share in 2019
Figure 32. Key Players Market Share Trend
Figure 33. Global Angiotensin Converting Enzyme Inhibitors Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 34. Global Angiotensin Converting Enzyme Inhibitors Revenue Market Share by Regions (2015-2020)
Figure 35. Global Angiotensin Converting Enzyme Inhibitors Revenue Market Share by Regions in 2018
Figure 36. North America Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
Figure 37. Europe Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
Figure 38. Asia-Pacific Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
Figure 39. South America Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
Figure 40. Middle East and Africa Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
Figure 41. North America Angiotensin Converting Enzyme Inhibitors Revenue Market Share by Countries (2015-2020)
Figure 42. North America Angiotensin Converting Enzyme Inhibitors Revenue Market Share by Countries in 2019
Figure 43. USA Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
Figure 44. Canada Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
Figure 45. Mexico Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
Figure 46. Europe Angiotensin Converting Enzyme Inhibitors Revenue Market Share by Countries (2015-2020)
Figure 47. Europe Angiotensin Converting Enzyme Inhibitors Revenue Market Share by Countries in 2019
Figure 48. Germany Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
Figure 49. UK Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
Figure 50. France Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
Figure 51. Russia Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
Figure 52. Italy Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
Figure 53. Asia-Pacific Angiotensin Converting Enzyme Inhibitors Revenue Market Share by Countries (2015-2020)
Figure 54. Asia-Pacific Angiotensin Converting Enzyme Inhibitors Revenue Market Share by Countries in 2019
Figure 55. China Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
Figure 56. Japan Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
Figure 57. Korea Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
Figure 58. India Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
Figure 59. Southeast Asia Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
Figure 60. South America Angiotensin Converting Enzyme Inhibitors Revenue Market Share by Countries (2015-2020)
Figure 61. South America Angiotensin Converting Enzyme Inhibitors Revenue Market Share by Countries in 2019
Figure 62. Brazil Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
Figure 63. Argentina Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
Figure 64. Middle East and Africa Angiotensin Converting Enzyme Inhibitors Revenue Market Share by Countries (2015-2020)
Figure 65. Middle East and Africa Angiotensin Converting Enzyme Inhibitors Revenue Market Share by Countries in 2019
Figure 66. Saudi Arabia Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
Figure 67. UAE Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
Figure 68. Egypt Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
Figure 69. South Africa Angiotensin Converting Enzyme Inhibitors Revenue and Growth Rate (2015-2020)
Figure 70. Global Angiotensin Converting Enzyme Inhibitors Revenue Share by Type (2015-2020)
Figure 71. Global Angiotensin Converting Enzyme Inhibitors Revenue Share by Type in 2019
Figure 72. Global Angiotensin Converting Enzyme Inhibitors Market Share Forecast by Type (2021-2025)
Figure 73. Global Benazepril (Lotensin) Revenue Growth Rate (2015-2020)
Figure 74. Global Captopril Revenue Growth Rate (2015-2020)
Figure 75. Global Enalapril (Vasotec) Revenue Growth Rate (2015-2020)
Figure 76. Global Fosinopril Revenue Growth Rate (2015-2020)
Figure 77. Global Lisinopril (Prinivil, Zestril) Revenue Growth Rate (2015-2020)
Figure 78. Global Moexipril Revenue Growth Rate (2015-2020)
Figure 79. Global Perindopril Revenue Growth Rate (2015-2020)
Figure 80. Global Quinapril (Accupril) Revenue Growth Rate (2015-2020)
Figure 81. Global Ramipril (Altace) Revenue Growth Rate (2015-2020)
Figure 82. Global Trandolapril Revenue Growth Rate (2015-2020)
Figure 83. Global Angiotensin Converting Enzyme Inhibitors Revenue Share by Application (2015-2020)
Figure 84. Global Angiotensin Converting Enzyme Inhibitors Revenue Share by Application in 2019
Figure 85. Global Angiotensin Converting Enzyme Inhibitors Market Share Forecast by Application (2021-2025)
Figure 86. Global Coronary Artery Disease Revenue Growth Rate (2015-2020)
Figure 87. Global Heart Failure Revenue Growth Rate (2015-2020)
Figure 88. Global Diabetes Revenue Growth Rate (2015-2020)
Figure 89. Global Chronic Kidney Diseases Revenue Growth Rate (2015-2020)
Figure 90. Global Heart Attacks Revenue Growth Rate (2015-2020)
Figure 91. Global Scleroderma Revenue Growth Rate (2015-2020)
Figure 92. Global Migraines Revenue Growth Rate (2015-2020)
Figure 93. Global Others Revenue Growth Rate (2015-2020)
Figure 94. Global Angiotensin Converting Enzyme Inhibitors Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 95. Global Angiotensin Converting Enzyme Inhibitors Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 96. Global Angiotensin Converting Enzyme Inhibitors Revenue Market Share Forecast by Regions (2021-2025)
Figure 97. North America Angiotensin Converting Enzyme Inhibitors Revenue Market Forecast (2021-2025)
Figure 98. Europe Angiotensin Converting Enzyme Inhibitors Revenue Market Forecast (2021-2025)
Figure 99. Asia-Pacific Angiotensin Converting Enzyme Inhibitors Revenue Market Forecast (2021-2025)
Figure 100. South America Angiotensin Converting Enzyme Inhibitors Revenue Market Forecast (2021-2025)
Figure 101. Middle East and Africa Angiotensin Converting Enzyme Inhibitors Revenue Market Forecast (2021-2025)
Figure 102. Sales Channel: Direct Channel vs Indirect Channel
酵素阻害剤の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The global Enzyme Inhibitors market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 0.8% in the forecast period of 2020 to 2025 and will expected to reach USD 152460 million by 2025, from USD 147910 million in 2019. The Enzyme Inhibitors …- バーター症候群薬の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Bartter Syndrome Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Bartter Syndrome Drugs…
- バーター症候群治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Bartter Syndrome Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Bartter Syndrome T…
- アルポート症候群治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Alport Syndrome Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizat…
- 降圧薬の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The global Antihypertensive market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 2.0% in the forecast period of 2020 to 2025 and will expected to reach USD 21480 million by 2025, from USD 19810 million in 2019. The Antihypertensive mark…